Authors
Gary L Davis, Rafael Esteban-Mur, Vinod Rustgi, John Hoefs, Stuart C Gordon, Christian Trepo, Mitchell L Shiffman, Stefan Zeuzem, Antonio Craxi, Mei-Hsiu Ling, Janice Albrecht
Publication date
1998/11/19
Journal
New England journal of medicine
Volume
339
Issue
21
Pages
1493-1499
Publisher
Massachusetts Medical Society
Description
Background
Interferon alfa is the only effective treatment for patients with chronic hepatitis C. Forty percent of patients have an initial response to this therapy, but most subsequently relapse. We compared the effect of interferon alone with that of interferon plus oral ribavirin for relapses of chronic hepatitis C.
Methods
We studied 345 patients with chronic hepatitis C who relapsed after interferon treatment. A total of 173 patients were randomly assigned to receive standard-dose recombinant interferon alfa-2b concurrently with ribavirin (1000 to 1200 mg orally per day, depending on body weight) for six months, and 172 patients were assigned to receive interferon and placebo.
Results
At the completion of treatment, serum levels of hepatitis C virus (HCV) RNA were undetectable in 141 of the 173 patients who were treated with interferon and ribavirin and in 80 of the 172 patients who were treated with interferon …
Total citations
199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024510220717314314312412174705560583839282424151381058243
Scholar articles